Christos Sotiriou
Overview
Explore the profile of Christos Sotiriou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
287
Citations
25561
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Buisseret L, Loirat D, Aftimos P, Maurer C, Punie K, Debien V, et al.
Nat Commun
. 2023 Dec;
14(1):8223.
PMID: 38086864
No abstract available.
12.
De Caluwe A, Romano E, Poortmans P, Gombos A, Agostinetto E, Marta G, et al.
J Immunother Cancer
. 2023 Dec;
11(12).
PMID: 38056900
Background: Luminal B breast cancer (BC) presents a worse prognosis when compared with luminal A BC and exhibits a lower sensitivity to chemotherapy and a lower immunogenicity in contrast to...
13.
Rediti M, Fernandez-Martinez A, Venet D, Rothe F, Hoadley K, Parker J, et al.
Nat Commun
. 2023 Nov;
14(1):7053.
PMID: 37923752
The identification of prognostic markers in patients receiving neoadjuvant therapy is crucial for treatment optimization in HER2-positive breast cancer, with the immune microenvironment being a key factor. Here, we investigate...
14.
Buisseret L, Loirat D, Aftimos P, Maurer C, Punie K, Debien V, et al.
Nat Commun
. 2023 Nov;
14(1):7018.
PMID: 37919269
Chemo-immunotherapy is the first-line standard of care for patients with PD-L1 positive metastatic triple-negative breast cancer (mTNBC). SYNERGY (NCT03616886) is a dose-finding phase I and a randomized phase II, open-label...
15.
Joaquin Garcia A, Rediti M, Venet D, Majjaj S, Kammler R, Munzone E, et al.
Clin Cancer Res
. 2023 Sep;
29(23):4908-4919.
PMID: 37733800
Purpose: To explore whether specific triple-negative breast cancer (TNBC) molecular subtypes are predictive for a benefit from maintenance low-dose cyclophosphamide and methotrexate (CM) in the adjuvant IBCSG 22-00 phase III...
16.
Thagaard J, Broeckx G, Page D, Jahangir C, Verbandt S, Kos Z, et al.
J Pathol
. 2023 Aug;
260(5):498-513.
PMID: 37608772
The clinical significance of the tumor-immune interaction in breast cancer is now established, and tumor-infiltrating lymphocytes (TILs) have emerged as predictive and prognostic biomarkers for patients with triple-negative (estrogen receptor,...
17.
Page D, Broeckx G, Jahangir C, Verbandt S, Gupta R, Thagaard J, et al.
J Pathol
. 2023 Aug;
260(5):514-532.
PMID: 37608771
Modern histologic imaging platforms coupled with machine learning methods have provided new opportunities to map the spatial distribution of immune cells in the tumor microenvironment. However, there exists no standardized...
18.
Lengrand J, Pastushenko I, Vanuytven S, Song Y, Venet D, Sarate R, et al.
Nature
. 2023 Aug;
620(7973):402-408.
PMID: 37532929
Epithelial-to-mesenchymal transition (EMT) regulates tumour initiation, progression, metastasis and resistance to anti-cancer therapy. Although great progress has been made in understanding the role of EMT and its regulatory mechanisms in...
19.
Nguyen H, Geukens T, Maetens M, Aparicio S, Bassez A, Borg A, et al.
Nat Commun
. 2023 Jul;
14(1):4418.
PMID: 37479706
Obesity is associated with an increased risk of developing breast cancer (BC) and worse prognosis in BC patients, yet its impact on BC biology remains understudied in humans. This study...
20.
Caparica R, Richard F, Brandao M, Awada A, Sotiriou C, de Azambuja E
Clin Breast Cancer
. 2023 May;
23(5):e281-e284.
PMID: 37183094
No abstract available.